Online ISSN: 1949-2553
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

AI for Improved PET/CT Attenuation Correction in Prostate Cancer Imaging

Oncotarget

July 11, 2024
In this new study, researchers investigated an artificial intelligence (AI) tool that produces attenuation-corrected PET images while reducing radiation exposure for patients. continue reading »

Targeting ABC Transporters in PDAC – Past, Present, or Future?

News

July 10, 2024
PRESS RELEASE: On June 20, 2024, a new editorial was published in Oncotarget, entitled, “Targeting ABC transporters in PDAC – past, present, or future?” continue reading »

Regorafenib Synergizes With TAS102 Against Multiple Gastrointestinal Cancers

News

July 9, 2024
PRESS RELEASE: On July 2, 2024, a new research paper was published in Oncotarget, entitled, “Regorafenib synergizes with TAS102 against multiple gastrointestinal cancers [...].” continue reading »

Editorial: Genomics Has More to Reveal

News

July 2, 2024
PRESS RELEASE: On June 20, 2024, a new editorial was published in Oncotarget, entitled, “Genomics has more to reveal.” continue reading »

Starving Cancer Cells to Enhance DNA Damage and Immunotherapy Response

News

June 26, 2024
PRESS RELEASE: On June 20, 2024, a new research perspective was published in Oncotarget, entitled, “Starving cancer cells to enhance DNA damage and immunotherapy response.” continue reading »